Compare Lockheed Martin Corporation (LMT) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lockheed Martin Corporation vs Smith & Nephew plc — how do they compare? Lockheed Martin Corporation trades at $509.59 (market cap $117.22B), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: Lockheed Martin Corporation is far larger — about 10.6× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Lockheed Martin Corporation for 86 Days and Smith & Nephew plc for 121 Days on average.
| LMT | SNN | |
|---|---|---|
Market Cap | $117.22B | $11.10B |
Volume | 1,101,121 | 1,051,703 |
Sector | Industrials | Health |
52-Week High | $676.70 | $37.17 |
52-Week Low | $439.19 | $26.42 |
Typical Hold Time | 86 Days | 121 Days |
Enterprise Value | $133.96B | $14.13B |
Dividend Yield | 2.72% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lockheed Martin (LMT) trades at $509.59, up 2.08% over the past day, with a bearish technical signal but strong analyst consensus. The company reported mixed quarterly earnings, missing in Q4 2025 and Q1 2026 but beating in Q2 2026, while revenue and cash flow trends show growth. Recent news highlights innovation in AI and autonomous systems, dividend increases, and ongoing defense contracts, supporting a positive long-term outlook despite near-term volatility.
LMT presents a compelling investment case with a consensus price target of $635.33, implying significant upside, backed by robust cash flows and a dominant defense market position. Risks include reliance on government spending, fixed-price contract volatility, and rising debt levels, but the stock's current valuation and dividend track record offer a margin of safety for patient investors.
Smith+Nephew (SNN) trades at $27.24, near its 52-week low of $27.05, with a bearish technical signal despite recent earnings beats. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%, but the stock faces headwinds from analyst downgrades and CFO departure news. Product launches like the EVOS PELVIC System highlight innovation, yet investor sentiment remains cautious.
The outlook is mixed: strong fundamentals and undervaluation (P/E 18.34) offer upside, but technical weakness and competitive risks temper near-term gains. Key risks include execution challenges and market volatility, while institutional interest (e.g., BlackRock's $505M stake) provides support. Investors should weigh solid profitability against sentiment-driven price pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
